Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of psoriasis and psoriatic arthritis.

Controlling the relapses of scalp psoriasis is a clinical issue.

Who Took Part

According to the abstract, 211 patients were involved.

The participants were randomized 1: 1: 1 to the experimental (supramolecular active zinc antidandruff hair conditioner), placebo (supramolecular hydrogel) or positive control (calcipotriol ointment) group.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Zinc, Scalp, Psoriasis and Scalp Dermatoses.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 211 patients in people with psoriasis and psoriatic arthritis.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Clinical and experimental dermatology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Psoriasis and psoriatic arthritis research.